Aeglea BioTherapeutics Inc. , a cancer and metabolism biotechnology company, priced its offering at $10 a share early Thursday morning, below its initial price range of $16 to $18. The company increased the number of shares it sold to 5 million from 3.5 million shares to raise about $50 million. The company is also giving the underwriters a 30-day option to buy up to 750,000 additional shares of its stock. UBS Investment Bank, BMO Capital Markets, Wells Fargo acted as joint book-running managers with Needham & Co. acting as co-manager.The company plans to begin trading shares on the Nasdaq Thursday.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News